Идёт набор NCT07436455

F-18 Tetrafluoroborate PET/CT in Differentiated Thyroid Cancer

Без фазы С лечением Thyroid Cancer Differentiated Thyroid Cancer

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают: В протоколе указаны: F-18-Tetrafluoroborate PET/CT.
Кому может быть актуально: Состояния в реестре: Thyroid Cancer, Differentiated Thyroid Cancer. Базовые параметры: от 18 лет · Все.
Что важно проверить: Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится: Turkey (Türkiye)
Следующий шаг: Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Обзор

In patients who have undergone surgery for differentiated thyroid cancer and who demonstrate elevated serum Tg and/or ATg levels during follow-up after radioactive iodine therapy, lesion detection is performed using neck ultrasonography, thorax CT, and F-18 FDG PET/CT. Diagnostic whole-body scanning with low-dose I-131 is not routinely recommended in follow-up due to its low sensitivity and specificity. F-18 TFB is a highly specific imaging agent for differentiated thyroid cancer, entering thyroid follicular epithelial cells via the sodium-iodide symporter (NIS), which is expressed on the cell surface and functions through a mechanism similar to that of I-131. As a PET radiotracer, F-18 TFB has been shown to be superior to I-131 in previous studies. The primary aim of this study is to comparatively evaluate the role of F-18 TFB PET/CT versus the standard imaging modality F-18 Fluorodeoxyglucose (FDG) PET/CT in lesion detection in patients with differentiated thyroid cancer who demonstrate elevated serum Tg and/or ATg levels during follow-up after radioactive iodine therapy. The secondary aims are to investigate the factors predicting F-18 TFB PET/CT positivity and to assess the relationship between the semi-quantitative and quantitative parameters derived from F-18 TFB PET/CT and serum thyroglobulin (Tg) and anti-thyroglobulin (ATg) levels.

Вмешательства

Диагностический тест F-18-Tetrafluoroborate PET/CT
F-18-Tetrafluoroborate whole body PET/CT

Первичные конечные точки

Diagnostic accuracy of F-18-TFB PET/CT [Срок оценки: From enrollment of the first patient, 9 months]

Вторичные конечные точки (3)

F-18 TFB PET/CT positivity [Срок оценки: From enrollment of the first patient, 9 months]
Correlation Between 18F-TFB PET/CT SUVmax (g/mL) and Serum Thyroglobulin Concentration (ng/mL) [Срок оценки: From enrollment of the first patient, 9 months]
Correlation Between 18F-TFB PET/CT SUVmax (g/mL) and Serum Anti-Thyroglobulin Levels (IU/mL) [Срок оценки: From enrollment of the first patient, 9 months]

Критерии участия

Критерии включения

Having undergone surgery for differentiated thyroid cancer and received radioactive iodine therapy
Being evaluated for lesion detection due to elevated serum Tg and/or ATg levels during post-treatment follow-up
Negative or equivocal I-131 whole-body scan findings
Karnofsky Performance Status ≥ 50 (or equivalent Eastern Cooperative Oncology Group \[ECOG\]/World Health Organization \[WHO\] performance status)
Giving written informed consent